Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression
- 27 March 2013
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 28 (2) , 151-159
Abstract
Objectives: Anxiety in major depression is associated with increased morbidity. The antidepressant, agomelatine, which acts as an agonist at melatonin MT1 and MT2 receptors and as an antagonist at serotonin 5‐HT2C receptors, has demonstrated efficacy and safety in both major depression and generalized anxiety disorder. Here, we investigated the efficacy of agomelatine in anxious depression.Methods: Data from three placebo‐controlled short‐term trials of agomelatine and three comparative studies of agomelatine versus fluoxetine, sertraline, and venlafaxine were pooled. Effects of agomelatine on anxiety symptoms were assessed with the Hamilton Anxiety Rating Scale in four studies (one vs placebo and three vs active comparator) and with the Hamilton Depression Rating Scale (HAMD) anxiety subscore in all six studies. Anxiolytic and antidepressant efficacies of agomelatine were assessed in patients with more severe anxiety symptoms at baseline (score ≥5 on HAMD anxiety subscore).Results: Agomelatine had a significantly greater effect on anxiety symptoms than both placebo and a number of comparator antidepressants. In more anxious depressed patients, agomelatine had a significantly greater effect on anxiety and depressive symptoms than both placebo and comparator antidepressants.Conclusion: Once‐a‐day oral agomelatine is a new, efficacious alternative option for the treatment of anxiety in patients with major depression. Copyright © 2013 John Wiley & Sons, Ltd.Keywords
This publication has 42 references indexed in Scilit:
- Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive DisorderThe Journal of Clinical Psychiatry, 2010
- Investigating differential symptom profiles in major depressive episode with and without generalized anxiety disorder: true co-morbidity or symptom similarity?Psychological Medicine, 2009
- Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorderInternational Journal of Neuropsychopharmacology, 2009
- Efficacy of Agomelatine in Generalized Anxiety DisorderJournal of Clinical Psychopharmacology, 2008
- Which presenteeism measures are more sensitive to depression and anxiety?Journal of Affective Disorders, 2007
- Escitalopram and paroxetine in the treatment of generalised anxiety disorderThe British Journal of Psychiatry, 2006
- Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trialsJournal of Affective Disorders, 2005
- Quality-of-Life Impairment in Depressive and Anxiety DisordersAmerican Journal of Psychiatry, 2005
- Is antidepressant–benzodiazepine combination therapy clinically more useful?Journal of Affective Disorders, 2001
- Once-Daily Venlafaxine Extended Release (XR) Compared With Fluoxetine in Outpatients With Depression and AnxietyThe Journal of Clinical Psychiatry, 1999